Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report. (28th January 2020)

• Record Type: Journal Article
• Authors: Miklos, Udvardy; Strugov, Vladimir; Lewerin, Catharina; Grosicki, Sebastian; Mazur, Grzegorz; Steurer, Michael; Montillo, Marco; Kryachok, Irina; Middeke, Jan M.; Rekhtman, Grygoriy; Stefanelli, Tommaso; Vincent, Ghislaine; Govindaraju, Sameera; Österborg, Anders
• Is Part Of: British journal of haematology. Volume 189:Number 4(2020)
• Page Start: 689
• Page End: 693
• Publication Date: 2020-01-28
• Subjects: ofatumumab -- physician choice -- chronic lymphocytic leukaemia; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16429
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine‐refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician's choice. The five‐year follow‐up of this phase 3 trial showed that ofatumumab therapy resulted in a numerically but not significantly longer overall survival. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small‐molecule inhibitors. Ofatumumab is a well‐tolerable treatment option in multiresistant advanced CLL.